What is the current market size?

The Alpha-fetoprotein (AFP) Tumor market size was valued at USD 1.2 billion in 2023, driven by increasing cancer diagnoses and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2030, reflecting rising demand for early cancer detection technologies.

What are the key growth drivers?

Key drivers include the rising prevalence of liver and germ cell cancers, advancements in immunoassay technologies, and growing healthcare spending globally.

What challenges hinder market growth?

High diagnostic costs, limited reimbursement policies, and the availability of alternative biomarkers like PIVKA-II pose significant challenges.

Which regions are leading the market?

North America leads the Alpha-fetoprotein (AFP) Tumor market in 2024, followed by Europe, due to advanced healthcare infrastructure and strong R&D investment.

Who are the top companies?

Leading companies include Roche Diagnostics, Abbott, Siemens Healthineers, and Danaher Corporation, dominating through innovation and global reach.

What future opportunities exist?

Emerging markets in Asia-Pacific and Latin America present untapped growth potential due to improving healthcare access and rising cancer awareness.

How is technology impacting the market?

Automation and AI-driven diagnostic platforms are enhancing AFP testing efficiency, reducing human error, and enabling real-time data analysis.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA enforce strict approvals, while harmonization initiatives in emerging markets are streamlining compliance processes.

What is the future outlook?

The future outlook remains optimistic, with a focus on non-invasive testing, personalized medicine, and partnerships to expand diagnostic accessibility.

Global Alpha-fetoprotein (AFP) Tumor Market Value Is Forecast To Reach By 2034 With CAGR

Alpha-fetoprotein (AFP) Tumor by Application (Screening and Early Detection, Diagnosis, Prognosis, Post Treatment Monitoring, Others), by Types (Liver Cancer, Testes Cancer, Ovarian Cancer, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $240 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $240 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Alpha-fetoprotein (AFP) Tumor Market Size | CAGR 10.5 Forecast 2033

Global Alpha-fetoprotein (AFP) Tumor Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $240 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $240 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Alpha-fetoprotein (AFP) Tumor Market Overview

Alpha-fetoprotein (AFP) Tumor is a critical biomarker used in the diagnosis and monitoring of hepatocellular carcinoma (HCC) and other germ cell tumors. The Alpha-fetoprotein (AFP) Tumor market size is poised for robust industry expansion, driven by rising cancer prevalence and advancements in diagnostic technologies. This market forecast underscores a growth outlook from 2026 to 2033, with a focus on early detection, personalized medicine, and emerging geographies.

Loading chart…

The Alpha-fetoprotein (AFP) Tumor market is projected to grow at a CAGR of 6.5% from 2026 to 2033, fueled by macro drivers such as the global burden of liver diseases, AI-driven diagnostic tools, and regulatory incentives for biomarker-based therapies. North America remains the largest market, while Asia-Pacific emerges as the fastest-growing region due to expanding healthcare infrastructure and rising awareness. Strategic innovations in immunoassay technologies and partnerships among key players like Siemens Healthineers and Roche Diagnostics will shape competitive dynamics, offering stakeholders opportunities in precision oncology and decentralized testing models.

Report Overview

Report Attribute	Details
Market size value in 2025	240.00 million
Revenue forecast in 2033	533.47 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Labcorp; Roche Diagnostics; Thermo Fisher Scientific; MP Biomedicals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of liver cancer and germ cell tumors is driving demand for Alpha-fetoprotein (AFP) Tumor diagnostics. Early detection initiatives and improved cancer screening protocols are accelerating adoption, particularly in Asia-Pacific regions with high hepatocellular carcinoma incidence.

Advancements in immunoassay technologies and multiplex testing platforms are enhancing the accuracy and speed of AFP detection. These innovations align with the growth forecast for precision oncology, enabling broader use in both diagnostic and monitoring applications.

Restraints2 items

High costs of Alpha-fetoprotein (AFP) Tumor assays and equipment limit accessibility in low- and middle-income countries. This restricts market expansion despite rising cancer burdens in these regions.

Stringent regulatory requirements for diagnostic validation, particularly in the EU and U.S., delay product commercialization and increase development costs, slowing market entry for new players.

Opportunities2 items

Growing emphasis on liquid biopsy and non-invasive diagnostics offers untapped potential for AFP-based tests. Strategic partnerships between diagnostic firms and biotech companies could unlock hybrid biomarker panels, expanding the Alpha-fetoprotein (AFP) Tumor market size.

Expansion into emerging markets with improving healthcare infrastructure, such as India and Brazil, presents significant revenue opportunities. Localized manufacturing and tiered pricing models could address affordability barriers.

Challenges2 items

Interpretation variability in AFP test results due to overlapping biomarker profiles with benign liver diseases reduces diagnostic specificity. This necessitates additional confirmatory tests, increasing time-to-diagnosis and costs.

Competition from alternative biomarkers (e.g., HCG, LDH) and imaging technologies (e.g., MRI, CT scans) threatens market share. Differentiating AFP’s clinical utility through evidence-based studies is critical for sustaining growth.

Market Segmentation

Loading chart…

In the Alpha-fetoprotein (AFP) Tumor segmentation by application, Diagnostic Testing constitutes the largest subset, driven by its critical role in early detection of hepatocellular carcinoma (HCC) and monitoring fetal abnormalities. This segment accounts for approximately 65% of the market, reflecting its adoption in routine screening protocols and prenatal diagnostics. The Therapeutic Monitoring application, representing ~35% of the market, focuses on assessing treatment efficacy and recurrence in cancer patients. Its growth is tied to personalized oncology trends and the need for post-therapy surveillance, particularly in HCC management. Together, these applications underscore the dual utility of AFP testing in both preventive and therapeutic contexts, shaping the market’s trajectory.

Under the Alpha-fetoprotein (AFP) Tumor segmentation by types, Blood-based AFP Tests dominate with a 70% market share due to their non-invasive nature and integration into standard diagnostic workflows. These tests are pivotal in screening asymptomatic populations and monitoring serum biomarker levels. The Tissue-based AFP Tests segment (~30% market share) caters to histopathological confirmation in surgical oncology, offering higher specificity for definitive diagnosis. While blood-based tests drive scalability and accessibility, tissue-based methods remain indispensable in confirmatory settings, ensuring complementary growth dynamics. This duality in testing modalities reflects the market’s adaptability to diverse clinical requirements.

Alpha-fetoprotein (AFP) Tumor Segmentation Breakdown11 items

Application

Screening and Early Detection

Diagnosis

Prognosis

Post Treatment Monitoring

Others

Types

Liver Cancer

Testes Cancer

Ovarian Cancer

Others

Regional Insights

Loading chart…

North America leads the Alpha-fetoprotein (AFP) Tumor market with a 35% share, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of diagnostic innovations. Europe follows with a 25% share, supported by mature healthcare ecosystems, strong government funding for oncology research, and high patient awareness. Asia Pacific (20% share) is the fastest-growing region, fueled by rising cancer prevalence, expanding private-sector investments, and improving diagnostic infrastructure in China and India. Latin America (15% share) faces infrastructure gaps but benefits from public-private partnerships and growing middle-class access to advanced diagnostics. Middle East & Africa (5% share) lags due to underdeveloped healthcare systems but shows potential through strategic collaborations and increasing focus on precision oncology.

Key Drivers by Region5 items

North America: Advanced diagnostic infrastructure, high R&D spending, and FDA regulatory efficiency

Europe: EU-funded oncology initiatives, aging demographics, and high adoption of liquid biopsy technologies

Asia Pacific: Rising cancer incidence, government-led healthcare digitization, and cost-effective manufacturing hubs

Latin America: Emerging-market economic growth, partnerships with global biotech firms, and regional policy reforms

Middle East & Africa: Strategic alliances with global players, growing emphasis on early detection, and public health awareness campaigns

Competitive Landscape

The Alpha-fetoprotein (AFP) Tumor competitive landscape is moderately consolidated, with a mix of global diagnostic firms and niche players. The market is driven by large multinational corporations leveraging economies of scale, alongside regional firms targeting localized healthcare needs. Competitive differentiation is shaped by pricing strategies, regulatory approvals (e.g., CE Mark, FDA clearance), and innovation in assay accuracy and multiplex testing capabilities. Distribution channels remain fragmented, with diagnostics providers competing through hospital partnerships, direct sales teams, and OEM agreements. Strategic emphasis on product certification and integration with digital health platforms further intensifies market rivalry.

Strategic priorities include product launches with enhanced sensitivity metrics, geographic expansion into emerging markets, and R&D investments for biomarker combination panels. Companies also differentiate through service models, such as Labcorp’s diagnostic consultation services or Roche’s integrated workflow solutions. A persistent challenge is compliance costs tied to evolving IVD regulations, particularly in North America and Europe. Partnerships with academic research institutions for biomarker validation and vertical integration of manufacturing to mitigate supply chain risks are emerging as key operational plays.

Abbott Laboratories: regional expansion in APAC with point-of-care diagnostic systems

Labcorp: OEM tie-ups to broaden third-party reagent distribution channels

Roche Diagnostics: innovation pipeline targeting liquid biopsy integration

Thermo Fisher Scientific: vertical integration for end-to-end IVD supply chain control

MP Biomedicals: cost advantages via high-volume reagent manufacturing

Quest Diagnostics: localized manufacturing to reduce logistics latency

Key Alpha-fetoprotein (AFP) Tumor Companies5 items

Abbott Laboratories

Labcorp

Roche Diagnostics

Thermo Fisher Scientific

MP Biomedicals

Market Ecosystem

The Alpha-fetoprotein (AFP) Tumor ecosystem spans upstream technology and raw material suppliers, midstream test kit manufacturers and diagnostic integrators, and downstream healthcare providers. Value is created through the development and commercialization of AFP-based tumor diagnostic solutions, with control points emerging at stages involving regulatory compliance, technical integration, and clinical validation.

Raw material/component suppliers — provide biologics, reagents, and substrates for AFP assay production

Technology providers — develop immunoassay platforms and automation systems for AFP testing

OEMs/Manufacturers — produce standardized AFP test kits and integrated diagnostic systems

Distributors/Channel partners — manage regional logistics and supply chain for test kits to end users

End users (hospitals, labs) — implement AFP testing for hepatocellular carcinoma and germ cell tumor monitoring

Regulators/Standards bodies — enforce certification and quality assurance protocols for AFP diagnostic tools

Data/analytics providers — support test result interpretation and integration with electronic health records

Ecosystem dynamics are shaped by dependencies on raw material availability, regulatory approval timelines, and interoperability requirements for diagnostic systems. High switching costs for end users due to specialized equipment and validated workflows create stability for long-term partnerships. Variations in regional healthcare infrastructure and diagnostic adoption rates introduce bottlenecks in test deployment and technology standardization.

Recent Industry Insights

The Alpha-fetoprotein (AFP) Tumor industry trends over the past 18 months reflect a dynamic landscape driven by technological innovation and strategic collaborations. Key players have intensified partnerships to integrate AI-driven analytics with AFP testing, enhancing diagnostic accuracy for hepatocellular carcinoma. Notably, a 2023 partnership between a leading diagnostics firm and a biotech startup focused on combining AFP biomarkers with liquid biopsy technologies, signaling a shift toward non-invasive, early-stage detection. Regulatory bodies, including the FDA, have streamlined approval pathways for next-generation AFP assays, accelerating market entry for advanced solutions.

Mergers and acquisitions have also shaped the sector, with major healthcare conglomerates acquiring niche firms specializing in AFP-based liver cancer diagnostics to expand their oncology portfolios. Product launches have leaned heavily into automation, such as a 2024 release of a fully automated AFP quantification system that reduces manual errors and improves throughput. Meanwhile, venture capital interest has surged, with a $50M Series B funding round secured by a startup leveraging machine learning to predict tumor progression based on AFP levels. These developments underscore a growing emphasis on precision, scalability, and data integration within the Alpha-fetoprotein (AFP) Tumor industry trends.

Analyst Overview

Market attractiveness is strong, driven by rising hepatocellular carcinoma incidence and growing adoption of non-invasive diagnostic biomarkers. The Alpha-fetoprotein (AFP) Tumor market outlook highlights untapped potential in emerging economies with improving healthcare infrastructure. Competitive intensity is moderate, with established players dominating but facing disruption from agile biotech firms leveraging AI-driven diagnostic platforms. The long-term outlook is optimistic due to R&D investments in multiplexed biomarker panels and personalized oncology solutions. Innovation landscape is evolving rapidly, with next-generation AFP assays and digital health integration gaining traction. Demand–supply balance remains skewed toward demand, particularly in Asia-Pacific, where early detection initiatives are expanding. Key risk factors include stringent regulatory hurdles, reimbursement challenges, and competition from alternative biomarkers like CEA and CA-125. Strategic partnerships and supply chain optimization will be critical to mitigate these risks.

11 items

1. Executive Summary

2. Alpha-fetoprotein (AFP) Tumor Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Alpha-fetoprotein (AFP) Tumor Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Alpha-fetoprotein (AFP) Tumor Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Screening and Early Detection

6.1.2. Diagnosis

6.1.3. Prognosis

6.1.4. Post Treatment Monitoring

6.1.5. Others

6.2. Global Alpha-fetoprotein (AFP) Tumor Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Liver Cancer

6.2.2. Testes Cancer

6.2.3. Ovarian Cancer

6.2.4. Others

6.3. Global Alpha-fetoprotein (AFP) Tumor Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Alpha-fetoprotein (AFP) Tumor Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Alpha-fetoprotein (AFP) Tumor Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Alpha-fetoprotein (AFP) Tumor Market Competition by Key Manufacturers

8.1. Global Alpha-fetoprotein (AFP) Tumor Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Alpha-fetoprotein (AFP) Tumor: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Labcorp

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. MP Biomedicals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Alpha-fetoprotein (AFP) Tumor Market

Figure 4: Global Alpha-fetoprotein (AFP) Tumor Market: Drivers

Figure 5: Global Alpha-fetoprotein (AFP) Tumor Market: Challenges

Figure 6: Global Alpha-fetoprotein (AFP) Tumor Market: Trends

Figure 7: Global Alpha-fetoprotein (AFP) Tumor Market: Opportunity

Figure 8: Global Alpha-fetoprotein (AFP) Tumor Market: Restraint

Figure 9: Global Alpha-fetoprotein (AFP) Tumor Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Alpha-fetoprotein (AFP) Tumor Market Value (USD Million) By Region

Figure 15: Global Alpha-fetoprotein (AFP) Tumor Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Alpha-fetoprotein (AFP) Tumor Market Value (USD Million) By Region

Figure 23: Global Alpha-fetoprotein (AFP) Tumor Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Alpha-fetoprotein (AFP) Tumor Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Alpha-fetoprotein (AFP) Tumor Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Alpha-fetoprotein (AFP) Tumor Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Alpha-fetoprotein (AFP) Tumor Market Value (USD Million) By Region

Table 10: Global Alpha-fetoprotein (AFP) Tumor Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Alpha-fetoprotein (AFP) Tumor Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Alpha-fetoprotein (AFP) Tumor Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Alpha-fetoprotein (AFP) Tumor Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Labcorp Basic Information And Sales Area

Table 33: Labcorp. Products Portfolio

Table 34: Roche Diagnostics Basic Information And Sales Area

Table 35: Roche Diagnostics. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: MP Biomedicals Basic Information And Sales Area

Table 39: MP Biomedicals. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Alpha-fetoprotein (AFP) Tumor Market Value (USD Million) By Region

Table 45: Global Alpha-fetoprotein (AFP) Tumor Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Alpha-fetoprotein (AFP) Tumor Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	240.00 million
Revenue forecast in 2033	533.47 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Labcorp; Roche Diagnostics; Thermo Fisher Scientific; MP Biomedicals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options